Development of a magnetically-targeted, MRI-monitored nano-platform for brain tumor drug delivery.
Chertok, Beata
2009
Abstract
Brain tumors inflict a heavy burden of morbidity and high risk of death. Currently employed treatment modalities fail to substantially improve these dismal outcomes. Proteins have recently emerged as a new class of agent with potent anti-glioma activity. However, their therapeutic potential has been limited by formidable challenges in their delivery to brain tumor sites. This dissertation research investigated the feasibility of utilizing magnetic nanoparticles as a carrier for delivery of proteins to brain tumor lesions. Magnetic nanoparticles composed of a superparamagnetic core and a biocompatible polymeric shell presented a promising platform for this application. The core provided high saturation magnetization of 108 emu/g Fe, suggesting that the particles would be amenable to capture within a tumor lesion by an external magnetic field, a strategy termed <italic>magnetic targeting</italic>. Moreover, high T<sub>2</sub> relaxivity of 43 s<super>-1</super>mM<super> -1</super> indicated a possibility for non-invasive monitoring of nanocarrier delivery to the target site by <italic>in vivo</italic> T<sub>2</sub> MRI. Furthermore, the polysaccharide shell of the nanoparticles allowed successful loading of a model protein, beta-Galactosidase (betaGal), with a high loading capacity of 7.5% w/w. To deliver the nanocarriers to brain tumor lesions <italic> in vivo</italic>, an improved magnetic targeting methodology has been developed. This methodology involved administration of nanoparticles via carotid artery, optimization of the magnet configuration, and MRI-guided animal alignment with respect to mapped magnetic field topography. Animal studies in rats harboring 9L-gliosarcomas revealed that utilization of the developed methodology provided a 4.7-fold increase in tumor betaGal activity (636 +/- 42 muU/g tissue) compared to non-targeted control animals (134 +/- 46 muU/g tissue). In addition, high tumor selectivity of protein localization was observed, as tumor tissues displayed 7.5-fold higher betaGal activity (636 +/- 42 muU/g tissue) than the contra-lateral brain (85 +/- 30 muU/g tissue). Moreover, the delivery of the betaGal-loaded nanocarrier to the target site was successfully validated and quantified with non-invasive T<sub>2</sub> MRI. In conclusion, this work established the plausibility of protein delivery to brain tumor lesions using MRI-monitored magnetically-responsive nanoplatform in conjunction with developed magnetic targeting methodology. This accomplishment may pave the way to realization of efficacious protein-based therapies for brain cancer treatment.Subjects
Brain Tumors Development Drug Delivery Iron Oxide Nanoparticles Magnetic Targeting Magnetically Monitored Mri Nano Platform Protein Delivery Targeted Tumor
Types
Thesis
Metadata
Show full item recordCollections
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.